S 
Shaanxi Panlong Pharmaceutical Group Limited By Share 002864.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
22.21
+10.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.14bn
FY2016FY2025
Net income
CN¥96.3m
FY2016FY2025
Free cash flow
CN¥20.6m
FY2016FY2025
Shareholders' equity
CN¥1.69bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.14bn | CN¥973.9m | CN¥980.8m | CN¥974.3m | CN¥887.5m | CN¥670.3m | CN¥610.6m | CN¥489.4m | CN¥376.8m | CN¥305.4m |
| Gross profit | CN¥591.8m | CN¥592.1m | CN¥567.1m | CN¥566.0m | CN¥517.1m | CN¥414.8m | CN¥422.8m | CN¥348.2m | CN¥260.9m | CN¥192.4m |
| Research and development | CN¥53.1m | CN¥37.5m | CN¥20.3m | CN¥18.2m | CN¥14.0m | CN¥13.0m | CN¥13.1m | CN¥8.3m | CN¥7.2m | CN¥5.4m |
| Operating income | CN¥122.3m | CN¥138.4m | CN¥134.9m | CN¥123.0m | CN¥112.5m | CN¥95.0m | CN¥86.4m | CN¥66.2m | CN¥50.1m | CN¥44.8m |
| Net income | CN¥96.3m | CN¥120.3m | CN¥110.4m | CN¥101.2m | CN¥93.2m | CN¥79.1m | CN¥71.8m | CN¥64.7m | CN¥43.7m | CN¥39.5m |
| Diluted earnings per share | 0.91 | 1.18 | 0.97 | 1.18 | 1.09 | 0.93 | 0.84 | 0.76 | 0.59 | 0.60 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥2.32bn | CN¥2.28bn | CN¥2.13bn | CN¥1.93bn | CN¥1.33bn | CN¥1.16bn | CN¥928.9m | CN¥817.8m | CN¥752.9m | CN¥504.5m |
| Cash and short-term investments | — | CN¥1.17bn | CN¥1.10bn | CN¥823.4m | CN¥419.3m | CN¥382.0m | CN¥167.9m | CN¥85.1m | CN¥301.5m | CN¥125.7m |
| Total liabilities | CN¥633.8m | CN¥642.8m | CN¥573.8m | CN¥983.2m | CN¥523.0m | CN¥426.9m | CN¥254.2m | CN¥206.2m | CN¥197.3m | CN¥176.7m |
| Debt | — | CN¥150.8m | CN¥102.5m | CN¥427.2m | CN¥143.9m | CN¥107.0m | −CN¥2.2m | — | CN¥3.0m | CN¥20.0m |
| Shareholders' equity | CN¥1.69bn | CN¥1.64bn | CN¥1.55bn | CN¥929.7m | CN¥791.4m | CN¥720.8m | CN¥674.7m | CN¥611.6m | CN¥555.6m | CN¥327.8m |
| Shares outstanding | 106m | 102m | 114m | 86m | 85m | 85m | 86m | 85m | 74m | 66m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥63.0m | CN¥156.6m | CN¥104.0m | CN¥125.4m | CN¥116.0m | CN¥92.2m | CN¥67.9m | CN¥46.8m | CN¥28.4m | CN¥62.0m |
| Capital spending | −CN¥42.4m | −CN¥82.1m | −CN¥62.5m | −CN¥55.8m | −CN¥80.7m | −CN¥71.2m | −CN¥33.6m | −CN¥20.1m | −CN¥23.4m | −CN¥17.1m |
| Free cash flow | CN¥20.6m | CN¥74.5m | CN¥41.5m | CN¥69.5m | CN¥35.4m | CN¥21.1m | CN¥34.3m | CN¥26.8m | CN¥5.0m | CN¥44.9m |
| Dividends paid | −CN¥43.9m | −CN¥24.5m | −CN¥24.3m | −CN¥21.1m | −CN¥17.9m | −CN¥13.0m | −CN¥8.7m | −CN¥8.7m | −CN¥358,875 | −CN¥1.3m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥200.0m | CN¥222.5m | CN¥299.4m | CN¥267.4m | CN¥323.8m | CN¥250.2m | CN¥256.9m | CN¥261.6m |
| Gross profit | CN¥121.8m | CN¥122.1m | CN¥148.5m | CN¥150.3m | CN¥158.2m | CN¥134.9m | CN¥149.3m | CN¥158.7m |
| Operating income | CN¥27.1m | CN¥35.6m | CN¥19.4m | CN¥37.3m | CN¥34.4m | CN¥36.2m | CN¥40.3m | CN¥35.2m |
| Net income | CN¥20.6m | CN¥21.8m | CN¥6.5m | CN¥29.7m | CN¥28.9m | CN¥31.2m | CN¥30.7m | CN¥29.9m |
| Diluted earnings per share | 0.19 | 0.21 | 0.06 | 0.28 | 0.27 | 0.29 | 0.30 | 0.29 |
| Cash from operations | — | — | — | CN¥26.0m | CN¥36.0m | CN¥25.0m | CN¥28.0m | CN¥17.0m |
| Capital spending | −CN¥8.0m | −CN¥8.0m | — | −CN¥17.0m | −CN¥8.0m | −CN¥22.0m | −CN¥24.0m | −CN¥16.0m |
| Free cash flow | — | — | — | CN¥9.0m | CN¥28.0m | CN¥3.0m | CN¥4.0m | CN¥1.0m |
| Total assets | CN¥2.35bn | CN¥2.43bn | CN¥2.32bn | CN¥2.40bn | CN¥2.36bn | CN¥2.32bn | CN¥2.28bn | CN¥2.26bn |
| Cash and short-term investments | — | — | — | CN¥1.16bn | CN¥1.17bn | CN¥1.17bn | CN¥1.17bn | CN¥1.16bn |
| Debt | CN¥1.0m | CN¥100.0m | — | CN¥148.9m | CN¥148.5m | CN¥148.5m | CN¥148.5m | CN¥149.5m |
| Shareholders' equity | CN¥1.74bn | CN¥1.71bn | CN¥1.69bn | CN¥1.68bn | CN¥1.66bn | CN¥1.66bn | CN¥1.64bn | CN¥1.61bn |
Financial ratios
Data as of 21 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Gross margin | 51.9% | 60.8% | 57.8% | 58.1% | 58.3% | 61.9% | — |
| Operating margin | 9.7% | 14.2% | 13.8% | 13.7% | 12.7% | 14.5% | — |
| Net margin | 8.4% | 12.3% | 11.3% | 10.4% | 10.5% | 11.8% | — |
| Return on equity | 5.7% | 7.4% | 7.1% | 10.9% | 11.8% | 11.0% | — |
| Return on assets | 4.1% | 5.3% | 5.2% | 5.2% | 7.0% | 6.8% | — |
| Free cash flow yield | — | — | 4.5% | 7.2% | 6.8% | 5.4% | 3.9% |
| Revenue growth | 17.1% | -0.7% | 0.7% | 9.8% | 32.4% | 9.8% | — |
| Earnings growth | -19.9% | 8.9% | 9.2% | 8.6% | 17.8% | 10.2% | — |
| Current ratio | 3.44x | 3.97x | 3.49x | 1.64x | 2.19x | 2.49x | — |
| Debt to equity | — | 0.09x | 0.06x | 0.46x | 0.18x | 0.14x | -0.00x |
| Equity ratio | 72.6% | 71.7% | 72.9% | 48.1% | 59.5% | 62.0% | — |
| Interest coverage | 50.88x | 88.73x | 21.75x | 9.48x | 30.47x | 32.42x | — |
| R&D as a share of sales | 4.7% | 3.9% | 2.1% | 1.9% | 1.6% | 1.9% | — |
| Buybacks as a share of market value | -3.7% | 10.1% | -32.3% | -0.9% | -0.1% | 1.0% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 5.4% | 11.2% | 16.1% |
| Operating income | -0.2% | 5.2% | 9.7% |
| Net income | -1.6% | 4.0% | 8.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 56.0% | 56.9% | 57.7% | 60.5% |
| Operating margin | 12.3% | 12.7% | 12.9% | 13.3% |
| Net margin | 10.2% | 10.5% | 10.7% | 11.3% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 26.1 | 19.9 | 30.5 | 25.3 | 22.0 | 20.8 | 25.3 | 32.2 | 37.3 |
| Price to sales | 2.2 | 2.5 | 3.4 | 2.6 | 2.3 | 2.5 | 3.0 | 4.3 | 4.3 |
Dividends and splits
Per share, in the currency the company pays
Paid for 8 years. Last went ex-dividend on 22 Jul 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.25 | 0.308 | 0.169 | 0.154 | 0.138 | 0.115 | 0.116 | 0.077 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.